By John Q. Hosedrinker 
During a recent executive order signing in the Oval Office, President Donald Trump highlighted the influence of Joe Rogan in initiating action to ease restrictions on psychedelic research. Trump stated that Rogan was among those who called, urging a move to address the potential of these substances for treating severe mental illness. Flanked by Rogan and other officials, Trump emphasized the life-changing potential of psychedelics for conditions like depression and for veterans. The executive order directs the FDA to expedite clinical trials and approval processes for drugs such as ibogaine, psilocybin, MDMA, and LSD, which are currently illegal.
Read the original article here
The news is buzzing about an executive order signed by Trump concerning psychedelic drugs, and notably, Joe Rogan was by his side for the occasion. This event has certainly sparked a lot of conversation, and it’s interesting to unpack the implications and reactions.
The executive order itself directs the Food and Drug Administration to push forward with clinical trials for psychedelics like ibogaine, psilocybin, MDMA, and LSD, aiming to expedite the approval process for any drugs found to be safe and effective. This move, from a federal perspective, signifies an effort to explore the therapeutic potential of these substances, many of which are currently illegal.
However, the presence of Joe Rogan at such a significant moment has become a central point of discussion, often overshadowing the specifics of the order. For many, Rogan’s attendance is seen as a clear indication of a political transaction, with some suggesting that Trump is essentially “buying” Rogan’s support or influence. This perspective points to Rogan’s past statements about being politically agnostic and, at times, critical of Trump, making his appearance feel like a notable shift or compromise.
The sentiment expressed by many is that Rogan has “sold out,” compromising his perceived principles for access or benefit. The narrative is that Trump, knowing Rogan’s considerable platform and audience, is leveraging this to gain favor or neutralize potential criticism, especially from someone who has expressed mixed feelings about him in the past. The idea is that Trump can’t afford to lose Rogan’s audience, and this executive order is a strategic move to keep him onside.
There’s also a strong current of skepticism regarding the actual impact of an executive order. Many are quick to point out that an executive order is not the same as signing a law. While it can influence how existing rules are interpreted and direct federal agencies, it doesn’t create new legislation. This leads to the interpretation that the signing might be more of a symbolic gesture or a “photo op” rather than a concrete policy change, especially considering that it doesn’t address the underlying reclassification of these drugs by the DEA, which is seen as a crucial step for widespread access.
The criticism extends to Rogan himself, with many questioning his authenticity and principles. The idea that he claims to be politically neutral while appearing at such a politically charged event is seen as disingenuous. Some feel that Rogan’s supporters, who often champion his non-political stance, are now in a contradictory position, needing to reconcile his actions with his proclaimed neutrality.
Furthermore, there’s a recurring theme that the “best possible experiment” in psychedelics would involve Trump himself experiencing a significant dose, with the implication that this might lead to a transformative or revealing outcome. This highlights a deep level of distrust and cynicism directed at Trump.
The presence of Rogan, a podcast host and comedian, at a presidential signing ceremony for a health-related executive order has also been met with bewilderment. Questions arise about why a psychiatrist or neuroscientist wasn’t the featured guest, suggesting that Rogan’s inclusion is purely for political optics rather than scientific or policy expertise.
Another significant point of contention is the perceived hypocrisy of federal efforts to expedite research on psychedelics while marijuana, a substance that has seen significant legalization movements, remains illegal at the federal level. This observation underscores a perceived inconsistency in the administration’s approach to drug policy.
Ultimately, the prevailing sentiment from many observers is one of deep suspicion, with the executive order and Rogan’s presence being viewed as a calculated political maneuver. While some acknowledge that the underlying intention of exploring psychedelic therapies could be positive, the context of the signing, particularly Rogan’s involvement, casts a shadow over the initiative for many. The focus remains on what is perceived as a strategic alliance, with Rogan being seen as a willing participant in a transaction that compromises his earlier stances.